Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2015

Open Access 01-12-2015 | Research article

Genome-wide analysis of DNA methylation in subjects with type 1 diabetes identifies epigenetic modifications associated with proliferative diabetic retinopathy

Authors: Elisabet Agardh, Annika Lundstig, Alexander Perfilyev, Petr Volkov, Tove Freiburghaus, Eero Lindholm, Tina Rönn, Carl-David Agardh, Charlotte Ling

Published in: BMC Medicine | Issue 1/2015

Login to get access

Abstract

Background

Epigenetic variation has been linked to several human diseases. Proliferative diabetic retinopathy (PDR) is a major cause of vision loss in subjects with diabetes. However, studies examining the association between PDR and the genome-wide DNA methylation pattern are lacking. Our aim was to identify epigenetic modifications that associate with and predict PDR in subjects with type 1 diabetes (T1D).

Methods

DNA methylation was analyzed genome-wide in 485,577 sites in blood from cases with PDR (n = 28), controls (n = 30), and in a prospective cohort (n = 7). False discovery rate analysis was used to correct the data for multiple testing. Study participants with T1D diagnosed before 30 years of age and insulin treatment within 1 year from diagnosis were selected based on 1) subjects classified as having PDR (cases) and 2) subjects with T1D who had had diabetes for at least 10 years when blood DNA was sampled and classified as having no/mild diabetic retinopathy also after an 8.7-year follow-up (controls). DNA methylation was also analyzed in a prospective cohort including seven subjects with T1D who had no/mild diabetic retinopathy when blood samples were taken, but who developed PDR within 6.3 years (converters). The retinopathy level was classified by fundus photography.

Results

We identified differential DNA methylation of 349 CpG sites representing 233 unique genes including TNF, CHI3L1 (also known as YKL-40), CHN2, GIPR, GLRA1, GPX1, AHRR, and BCOR in cases with PDR compared with controls. The majority of these sites (79 %) showed decreased DNA methylation in cases with PDR. The Natural Killer cell-mediated cytotoxicity pathway was found to be significantly (P = 0.006) enriched among differentially methylated genes in cases with PDR. We also identified differential DNA methylation of 28 CpG sites representing 17 genes (e.g. AHRR, GIPR, GLRA1, and BCOR) with P <0.05 in the prospective cohort, which is more than expected by chance (P = 0.0096).

Conclusions

Subjects with T1D and PDR exhibit altered DNA methylation patterns in blood. Some of these epigenetic changes may predict the development of PDR, suggesting that DNA methylation may be used as a prospective marker of PDR.
Appendix
Available only for authorised users
Literature
1.
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64.CrossRefPubMedPubMedCentral
2.
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381–9.
3.
White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126:1707–15.CrossRefPubMed
4.
El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exper Med. 2008;205:2409–17.CrossRef
5.
6.
Miao F, Smith DD, Zhang L, Min A, Feng W, Natarajan R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes. 2008;57:3189–98.CrossRefPubMedPubMedCentral
7.
Nitert MD, Dayeh T, Volkov P, Elgzyri T, Hall E, Nilsson E, et al. Impact of an exercise intervention on DNA methylation in skeletal muscle from first-degree relatives of patients with type 2 diabetes. Diabetes. 2012;61:3322–32.CrossRefPubMedPubMedCentral
8.
Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, et al. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet. 2011;7:e1002300.CrossRefPubMedPubMedCentral
9.
Yang BT, Dayeh TA, Kirkpatrick CL, Taneera J, Kumar R, Groop L, et al. Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets. Diabetologia. 2011;54:360–7.CrossRefPubMed
10.
Yang BT, Dayeh TA, Volkov PA, Kirkpatrick CL, Malmgren S, Jing X, et al. Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes. Mol Endocrinol. 2012;26:1203–12.CrossRefPubMed
11.
Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S, Savage DA. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genet. 2010;3:33.
12.
Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011;98:288–95.CrossRefPubMed
13.
Rönn T, Volkov P, Davegardh C, Dayeh T, Hall E, Olsson AH, et al. A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. PLoS Genet. 2013;9:e1003572.CrossRefPubMedPubMedCentral
14.
Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics. 2013;8:203–9.CrossRefPubMedPubMedCentral
15.
Ohuchi H. Molecular aspects of eye evolution and development: from the origin of retinal cells to the future of regenerative medicine. Acta Med Okayama. 2013;67:203–12.PubMed
16.
Nguyen DV, Shaw LC, Grant MB. Inflammation in the pathogenesis of microvascular complications in diabetes. Front Endocrinol. 2012;3:170.CrossRef
17.
18.
Reis JS, Veloso CA, Mattos RT, Purish S, Nogueira-Machado JA. Oxidative stress: a review on metabolic signaling in type 1 diabetes. Arquivos Brasileiros Endocrinol Metabol. 2008;52:1096–105.
19.
20.
Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15:1875–91.CrossRefPubMed
21.
Freeman WM, Bixler GV, Brucklacher RM, Lin CM, Patel KM, VanGuilder HD, et al. A multistep validation process of biomarkers for preclinical drug development. Pharmacogenomics J. 2010;10:385–95.CrossRefPubMed
22.
Blum A, Socea D, Ben-Shushan RS, Keinan-Boker L, Naftali M, Segol G, et al. A decrease in VEGF and inflammatory markers is associated with diabetic proliferative retinopathy. Eur Cytokine Netw. 2012;23:158–62.PubMed
23.
Joergensen C, Hovind P, Schmedes A, Parving HH, Rossing P. Vitamin D levels, microvascular complications, and mortality in type 1 diabetes. Diabetes Care. 2011;34:1081–5.CrossRefPubMedPubMedCentral
24.
Muni RH, Kohly RP, Lee EQ, Manson JE, Semba RD, Schaumberg DA. Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmol. 2013;131:514–21.CrossRefPubMedPubMedCentral
25.
Agardh E. Rapid, bloody, and blinding diabetic retinopathy. Acta Ophthalmol (Copenh). 2010;88:274–8.CrossRef
26.
Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complicat. 2008;22:309–16.CrossRefPubMed
27.
28.
Sakamoto F, Katakami N, Kaneto H, Yasuda T, Takahara M, Miyashita K, et al. Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus. Endocr J. 2013;60:73–9.CrossRefPubMed
29.
Michelsen AE, Rathcke CN, Skjelland M, Holm S, Ranheim T, Krohg-Sorensen K, et al. Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis. 2010;211:589–95.CrossRefPubMed
30.
Hu C, Zhang R, Yu W, Wang J, Wang C, Pang C, et al. CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetic patients. Diabetes. 2011;60:3085–9.CrossRefPubMedPubMedCentral
31.
Sheu WH, Kuo JZ, Lee IT, Hung YJ, Lee WJ, Tsai HY, et al. Genome-wide association study in a Chinese population with diabetic retinopathy. Hum Mol Genet. 2013;22:3165–73.CrossRefPubMedPubMedCentral
32.
Cho GJ, Ryu S, Kim YH, Kim YS, Cheon EW, Park JM, et al. Upregulation of glucose-dependent insulinotropic polypeptide and its receptor in the retina of streptozotocin-induced diabetic rats. Curr Eye Res. 2002;25:381–8.CrossRefPubMed
33.
Allione A, Marcon F, Fiorito G, Guarrera S, Siniscalchi E, Zijno A, et al. Novel epigenetic changes unveiled by monozygotic twins discordant for smoking habits. PLoS One. 2015;10:e0128265.CrossRefPubMedPubMedCentral
34.
Monick MM, Beach SR, Plume J, Sears R, Gerrard M, Brody GH, et al. Coordinated changes in AHRR methylation in lymphoblasts and pulmonary macrophages from smokers. Am J Med Genet B Neuropsychiatr Genet. 2012;159B:141–51.CrossRefPubMedPubMedCentral
35.
Richmond RC, Simpkin AJ, Woodward G, Gaunt TR, Lyttleton O, McArdle WL, et al. Prenatal exposure to maternal smoking and offspring DNA methylation across the lifecourse: findings from the Avon Longitudinal Study of Parents and Children (ALSPAC). Hum Mol Genet. 2015;24:2201–17.CrossRefPubMed
36.
37.
Awata T, Yamashita H, Kurihara S, Morita-Ohkubo T, Miyashita Y, Katayama S, et al. A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA. PLoS One. 2014;9:e111715.CrossRefPubMedPubMedCentral
38.
39.
Dayeh TA, Olsson AH, Volkov P, Almgren P, Rönn T, Ling C. Identification of CpG-SNPs associated with type 2 diabetes and differential DNA methylation in human pancreatic islets. Diabetologia. 2013;56:1036–46.CrossRefPubMedPubMedCentral
40.
Olsson AH, Volkov P, Bacos K, Dayeh T, Hall E, Nilsson EA, et al. Genome-wide associations between genetic and epigenetic variation influence mRNA expression and insulin secretion in human pancreatic islets. PLoS Genet. 2014;10:e1004735.CrossRefPubMedPubMedCentral
Metadata
Title
Genome-wide analysis of DNA methylation in subjects with type 1 diabetes identifies epigenetic modifications associated with proliferative diabetic retinopathy
Authors
Elisabet Agardh
Annika Lundstig
Alexander Perfilyev
Petr Volkov
Tove Freiburghaus
Eero Lindholm
Tina Rönn
Carl-David Agardh
Charlotte Ling
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2015
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-015-0421-5

Other articles of this Issue 1/2015

BMC Medicine 1/2015 Go to the issue

Commentary

De-adoption and its 43 related terms: harmonizing low-value care terminology

Research article

The evolution of mobile apps for asthma: an updated systematic assessment of content and tools

Research article

Naive Bayes classifiers for verbal autopsies: comparison to physician-based classification for 21,000 child and adult deaths

Question and Answer

Lifestyle factors in preventing mental health disorders: an interview with Felice Jacka

Commentary

Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?

Research article

Western diet is associated with a smaller hippocampus: a longitudinal investigation